1. Introduction {#s0005}
===============

The blood-brain barrier (BBB) is a highly regulated interface between the brain and the rest of the body ([@b0005]). BBB permeability is an important aspect of several important neurological conditions such as multiple sclerosis and Alzheimer's disease ([@b0150]). Recent compelling evidence suggests that BBB integrity is an important player in the expression of neuropsychiatric manifestations of circulating anti-NMDA antibodies ([@b0055]). It is interesting to note that preceding systemic infections are very common in neuronal surface antibody-mediated encephalitis ([@b0075]); the aetiology of these prodromal infections are very varied, arguing against molecular mimicry, and perhaps more supportive of a generic effect of systemic infection on the BBB.

A number of *in vitro* and *in vivo* preclinical studies have shown that inflammatory challenge results in an increase in BBB permeability. This effect appears to be a feature of the BBB, unrelated to the type of inflammatory trigger since it has been observed in a wide variety of experimental settings including lipopolysaccharide, poly I:C, bacteria, viruses, chemically-induced inflammation, anaphylaxis and cytokines ([@b0150]). The main mechanisms underlying this phenomenon are tight junction changes and increased vesicular transport, but re-induction of fenestrae, endothelial cell damage, denudation of the glycocalyx, degradation of the glia limitans and astrocyte changes also play a role ([@b0150]).

While the effect of inflammatory challenges on human BBB permeability has been demonstrated *in vitro* using human brain microvessel endothelial cells ([@b0150]), the relevance of this large body of preclinical literature to the *in vivo* human situation remains to be shown. In this study, we set out to study the effect of systemic inflammation on human BBB permeability *in vivo* by examining the association between a panel of systemic inflammatory markers and the CSF/serum albumin quotient in 1273 consecutive unselected lumbar punctures. The CSF/serum albumin ratio (Q~alb~) is a widely accepted indicator of blood--CSF barrier function ([@b0130]). Since albumin is not synthesised in the brain, the ratio of CSF to serum albumin concentration is a quotient representing the fraction of serum albumin diffusing into the CSF, independent of serum concentration. Changes in serum albumin do not occur rapidly; hence CSF albumin can be assumed to be in constant equilibrium with serum as a function of BBB permeability. Immunoglobulins and cytokines are not suited for this type of study since they may be secreted intrathecally by blood-derived cells transmigrating into the brain. The effectiveness of Q~alb~ for measurement of BBB function has been demonstrated by studies with radiolabelled albumin ([@b0140]).

2. Methods and materials {#s0010}
========================

2.1. Data collection {#s0015}
--------------------

Data was collected by retrospective review of the medical records of 1273 individuals having lumbar puncture with Q~alb~ assessment at Southampton General Hospital, Hampshire, UK in a three year period (2011--2013), during a service evaluation, with institutional approval. The white cell count, neutrophil, lymphocyte, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) measurements within a five day period centred around the lumbar puncture were recorded ([Fig. 1](#f0005){ref-type="fig"}).

We additionally collected data on: age, CSF total protein, CSF glucose, CSF red and white blood cells, and oligoclonal bands. Cases were excluded if \<16 years of age and/or had a CSF red blood cell (RBC) count \>127 cells per microlitre. Since CSF total protein concentration rises by 1 mg/dl for every 100 red blood cells/μL that enter the CSF during traumatic lumbar puncture ([@b0015]), the CSF RBC count threshold was determined by calculating the maximum CSF RBC count which did not change any of the Q~alb~ values in the dataset.

CSF and blood were collected in sterile polypropylene tubes (Sterilin, Newport, Gwent, UK) and Vacutainers (Becton Dickinson, Plymouth, UK) respectively. CSF volume was not available. Samples were analysed on the same day, except for isoelectric focussing in which case samples were kept at 4 °C and batch analysed within one week. Blood counts were performed on a Sysmex XE-2100 automated hematology system. ESR was performed on a Vitech Starrsed system using the Westergren sedimentation method. CRP, albumin, protein and glucose were assayed on a Beckman Coulter AU5800 automated system. CSF cell counts were performed manually using a modified Fuchs-Rosenthal haemocytometer. Oligoclonal band assessment was performed manually using isoelectric focussing on CSF/serum pairs.

2.2. Data preparation {#s0020}
---------------------

Data preparation was performed in Excel v14. Cases were identified as having normal findings if the following conditions were met: CSF total protein \<500 mg/L, CSF glucose \>2/3 serum glucose, white blood cells ⩽5 cells/μL, polymorphs were absent, and there was no evidence of intrathecal synthesis of oligoclonal immunoglobulin G. Single systemic inflammatory variables included total leucocytes, neutrophils, lymphocytes, ESR and CRP; a composite variable (Inf~Blood~) integrating all these indices was created to reflect systemic inflammation. To reflect central nervous system inflammation, the variable Inf~CSF~ was derived from the CSF white cell count. The derivation of Inf~Blood~ and Inf~CSF~ is detailed in [Supplementary Methods](#s0070){ref-type="sec"}.

2.3. Statistical analysis {#s0025}
-------------------------

Statistical analysis was performed in SPSS v22. Since data was non-parametric, Mann-Whitney test was used for group comparisons. General linear model was used for analysis of covariance. Q~alb~, Inf~CSF~, and systemic inflammatory variables were logarithmically transformed. Multivariate linear regression was used to examine the association of systemic inflammatory markers with Q~alb~. A significant difference from the null hypothesis was assumed at p \< 0.05.

3. Results {#s0030}
==========

3.1. Characteristics of cases {#s0035}
-----------------------------

Out of a total of 1273 lumbar punctures, 829 cases were identified with a full CSF analysis including Q~alb~ and at least one systemic inflammatory variable result available within the 5 day period centred around the lumbar puncture. The characteristics of this study population are shown in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}. Median CRP was 4 mg/L, with an interquartile range of 14 mg/L, and mean CRP was 20 mg/L, with a standard deviation of 43 mg/L, representing predominantly mild-to-moderate systemic inflammation, rather than septic conditions.

3.2. Cases with normal CSF {#s0040}
--------------------------

In cases with normal CSF findings (n = 223), age, sex and Inf~Blood~ were entered as predictors in a multiple linear regression model with Q~alb~ as dependent variable ([Table 3](#t0015){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}A,B,C). Age was a significant predictor, sex was a borderline predictor, but none of the systemic inflammatory variables (composite or single) significantly predicted Q~alb~. Hence in individuals with a quiescent CSF, systemic inflammation was not associated with blood-CSF barrier permeability to albumin.

3.3. Cases with abnormal CSF {#s0045}
----------------------------

Q~alb~ was significantly higher in cases with abnormal CSF versus those with normal CSF (n = 606 and 223, medians of 0.007 and 0.005 respectively, p \< 10^−25^), and this effect was still significant in an analysis of covariance with age and sex (p \< 10^−8^). This was expected since several neurological diseases affect BBB permeability ([@b0110]). This finding confirmed the necessity to include CSF abnormality as a covariate while examining the effect of systemic inflammation on Q~alb~ in the presence of CSF abnormality. For this purpose, the CSF cell count was used as an indicator of CSF abnormality, in the form of the normalized variable Inf~CSF~.

Age, sex, Inf~Blood~ and Inf~CSF~ were entered as predictors in a multiple regression model with Q~alb~ as dependent variable. All four variables were significant predictors of Q~alb~ ([Table 3](#t0015){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"}D,E,F).

Inf~Blood~ predicted Q~alb~ in the presence of CSF abnormality, but not when CSF was normal. Hence the effect of systemic inflammation on Q~alb~ was different between cases with normal and abnormal CSF; an interaction between Inf~Blood~ and CSF normality was significant ([Fig. 3](#f0015){ref-type="fig"}, p = 0.009). In view of the known interplay between systemic and brain inflammation ([@b0025], [@b0035]), an interaction term between Inf~Blood~ and Inf~CSF~ was explored as a second block after age, sex, Inf~Blood~ and Inf~CSF~ across all cases; this was significant (p \< 0.03). In cases with abnormal CSF only, an interaction between Inf~Blood~ and Inf~CSF~ was examined in the regression analysis as a second block after age, sex, Inf~Blood~ and Inf~CSF~; a trend was observed but the interaction was not significant (p = 0.08).

When individual systemic inflammatory markers were examined, high CRP and neutrophils exhibited the same relationship with Inf~CSF~ and Q~alb~, but CRP exerted the highest influence on BBB permeability (beta = 0.128 and 0.077, p = 0.01 and 0.04 for CRP and neutrophils respectively). Hence CRP was the most sensitive systemic inflammatory marker impacting on BBB permeability.

3.4. Temporal analysis {#s0050}
----------------------

In order to investigate whether the relationship between systemic inflammation and Q~alb~ was cause or effect, a temporal analysis was undertaken. The multiple linear regression was re-run in cases with abnormal systemic inflammatory markers (Inf~Blood~, CRP or neutrophils) before the LP (n = 59), and in cases with normal systemic inflammatory markers before the LP but abnormal markers at or after the LP (n = 29). High systemic inflammatory markers (Inf~Blood~, CRP or neutrophils) were only predictive of an increased Q~alb~ when these systemic abnormalities were present before the LP (beta = 0.366, p = 0.001 for Inf~Blood~; beta = 0.234, p = 0.046 for CRP; beta = 0.314, p = 0.003 for neutrophils). This result is in keeping with a causative relationship of systemic inflammation on BBB breakdown, in the presence of intrathecal inflammation.

4. Discussion {#s0055}
=============

This study is the first to explore the association between systemic inflammation and BBB function in humans, demonstrating a vulnerability of the BBB in the diseased brain to the effect of systemic inflammation. While systemic inflammation did not affect the blood-CSF barrier in individuals with quiescent CSF, systemic inflammation significantly influenced blood-CSF barrier permeability in the presence of CSF abnormality. It is possible that the techniques used in this study were not sufficiently sensitive to detect an effect of systemic inflammation on BBB function in the healthy brain. In particular Q~alb~ may underestimate, or fail to detect, changes in BBB permeability to molecules smaller than albumin. Despite this limitation, this study has clearly demonstrated that the BBB in the diseased brain is more susceptible to systemic inflammation compared to the healthy brain. The BBB alterations which occur as a consequence of neuropathology ([@b0110]) may be responsible for this phenomenon.

The findings in this study are similar to observations in preclinical studies. In healthy animals, BBB permeability was significantly affected when septic doses, but not lower doses, of lipopolysaccharide were used ([@b0010], [@b0080]). In contrast, a more widespread increase in BBB permeability is seen after LPS challenge in animals with neuropathology such as experimental autoimmune encephalomyelitis, in brain ([@b0115]) and spinal cord ([@b0085]). Increased BBB vulnerability to systemic inflammation was seen in an Alzheimer disease mouse model, compared to wild-type mice ([@b0125]). Likewise, the BBB in ischaemic stroke is more susceptible to systemic inflammation ([@b0040]).

Systemic inflammation affects the course of neurological disease. Systemic infection causes accelerated cognitive decline in patients with AD ([@b0060]) and impairs outcome in stroke patients ([@b0120]). Experimentally-induced systemic inflammation in preclinical models of AD ([@b0035]) and stroke ([@b0040]) has confirmed a causative association. It is possible that the effect of systemic inflammation on the BBB may be one of the mechanisms underlying the worsening of neurological disease with systemic inflammation. In support of this, experimental disruption of the BBB results in neurological toxicity ([@b0135]) and experimental manoeuvres which strengthen the BBB result in improvement of pathology ([@b0065], [@b0100]). BBB alterations induced by systemic inflammation in AD favour increased amyloid deposition in the brain ([@b0080]).

Delirium is commonly caused by systemic infection ([@b0050]) or critical illness ([@b0095]), conditions associated with systemic inflammation. Elevated levels of serum S100B, a potential biomarker of BBB disruption ([@b0020]), have been observed during delirium in Alzheimer's disease ([@b0145]) and critical illness ([@b0070]). Since systemic inflammation affects the BBB, it is possible that increased BBB permeability is a mediator of delirium in conditions such as Alzheimer's disease and critical illness.

Both systemic infections and BBB permeability have been linked to clinical outcome. For example in experimental stroke, systemic IL1β challenge results in matrix metalloproteinase 9-induced BBB disruption, larger infarct size and poorer neurological outcome ([@b0090]). In multiple sclerosis, systemic infections occur in conjunction with gadolinium enhancement and clinical relapses ([@b0030]). Further work is needed to determine the importance of the *systemic infection → BBB breakdown → clinical outcome* mechanistic pathway in neurological patients. Prevention and/or aggressive treatment of systemic infections, and the use of agents which protect against or reverse systemic inflammation-induced increase in BBB permeability ([@b0090], [@b0155]) would be potential therapeutic avenues.

Future work is needed to address limitations of this study. Here, we have not systematically determined the precise reason for systemic raised inflammatory markers or abnormal CSF. Although preclinical studies have shown that the effect of systemic inflammation on BBB permeability occurs across a broad range of systemic inflammatory stimuli and neuropathologies ([@b0150]), future studies may explore which types of inflammatory stimuli and neuropathologies are combinatorially most conducive to an interaction between the periphery and the brain. Since this was a retrospective study, information on mental state or illness behaviour was not available. The use of Q~alb~ to evaluate BBB function has its own limitations, particularly the possibility of confounding by CSF bulk flow ([@b0105], [@b0130]), which can be influenced by systemic inflammation ([@b0045]). Finally since Q~alb~ represents the blood-CSF barrier, which is only one of the barriers in the central nervous system ([@b0005]), other methods of studying human BBB function *in vivo* such as dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) or circulating biomarkers of BBB integrity will be useful. Although this study provided some evidence in support of causation, prospective and/or experimental human studies would provide concrete proof that systemic inflammation affects BBB function.
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![Study design. FBC: full blood count, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein.](gr1){#f0005}

![Relationship between systemic inflammation and blood-brain barrier permeability in the presence of normal (A,B,C) and abnormal (D,E,F) CSF. Regression lines of Inf~Blood~ versus Q~alb~ across sex (A,D) and quantiles of age (B,E) and Inf~CSF~ (C,F). To generate this Figure, Q~alb~ was regressed against Inf~Blood~ across categories of sex (A,D), age (B,E) and Inf~CSF~ (C,F).](gr2){#f0010}

![Regression lines of Inf~Blood~ versus Q~alb~ showing relationship between systemic inflammation and blood-brain barrier permeability in cases with normal and abnormal CSF. To generate this Figure, Q~alb~ was regressed against Inf~Blood~, CSF normality and an interaction between Inf~Blood~ and CSF normality.](gr3){#f0015}

###### 

Demographics.

  Characteristic                                  
  ----------------------------------------------- ---------
  Number                                          829
  Age (years, ±SD)                                49 ± 17
  Sex (% male)                                    41%
  Timing of blood sample to lumbar puncture (%)   
   Before LP                                      38
   At LP                                          36
   After LP                                       26
  Final neurological diagnosis (%)                
   Inflammatory                                   31
   Idiopathic                                     12
   Degenerative                                   6
   Vascular                                       6
   Infectious                                     4
   Neoplastic                                     4
   Metabolic                                      1
   Miscellaneous                                  5
   Multiple neurological diagnoses                4
   No neurological diagnosis                      27

###### 

Laboratory parameters.

  Laboratory parameter (n with data)     \% normal   Median (IQR)   Mean (SD)   Reference range               
  -------------------------------------- ----------- -------------- ----------- ----------------- ----------- ------------------
  CSF normality (829)                    27          73                                                       
  Total white cell count (798)           82          14             4           7.5 (3.7)         8.3 (4.2)   4--11 × 10^9^/L
  Neutrophil count (797)                 80          17             3           4.6 (2.9)         5.5 (3.2)   2--7.5 × 10^9^/L
  Lymphocyte count (797)                 70          26             4           1.9 (0.9)         2 (1.3)     1.5--4 × 10^9^/L
  Erythrocyte sedimentation rate (297)   24          12             64          10 (19)           19 (23)     1--10 mm/h
  C-reactive protein (507)               38          23             39          4 (14)            20 (43)     0--7.5 mg/L
  Inf~Blood~ (829)                       66          34                                                       

###### 

Multiple linear regression of age, sex, Inf~CSF~ and Inf~Blood~ against Q~alb~.

  Variable                    Unstandardized Coefficient   Standardized Coefficient   p        
  --------------------------- ---------------------------- -------------------------- -------- ------------------------------------------
  *Cases with normal CSF*                                                                      
  Age                         0.008                        0.002                      0.324    \<0.01[∗](#tblfn20){ref-type="table-fn"}
  Gender                      −0.111                       0.061                      −0.119   0.07
  Ln Inf\[CSF\]               0.009                        0.016                      0.037    0.57
  Ln Inf\[Blood\]             0.001                        0.011                      0.003    0.96
                                                                                               
  *Cases with abnormal CSF*                                                                    
  Age                         0.009                        0.002                      0.219    \<0.01[∗](#tblfn20){ref-type="table-fn"}
  Gender                      −0.414                       0.054                      −0.282   \<0.01[∗](#tblfn20){ref-type="table-fn"}
  Ln Inf\[CSF\]               0.075                        0.011                      0.250    \<0.01[∗](#tblfn20){ref-type="table-fn"}
  Ln Inf\[Blood\]             0.029                        0.010                      0.107    \<0.01[∗](#tblfn20){ref-type="table-fn"}

p \< 0.05.
